Alacrita set to change the face of life science consulting

Alacrita, a newly created life science consultancy, is set to change the face of consulting in the sector. Alacrita has been formed by a broad team of consultants with real-world management experience of delivering success at all key points in the development of pharma and biotech companies and products. The team at Alacrita is focused on providing value added business solutions to a much broader range of companies across the sector in a timely and cost-effective manner.

Alacrita is led by its two founding partners Dr Anthony Walker and Rob Johnson. Dr Walker has a background as biotech CEO and as a management consultant to the pharma industry. He has previously worked for Onyvax, Arthur D Little and the Wilkerson Group. Rob Johnson has many years of biotech business development expertise gained while working at Onyvax. The founding partners at Alacrita are supported by more than 40 consultants with significant strategic, corporate, product development and regulatory experience in the life science sector.

Alacrita is led by its two founding partners Dr Anthony Walker and Rob Johnson. Dr Walker has a background as biotech CEO and as a management consultant to the pharma industry. He has previously worked for Onyvax, Arthur D Little and the Wilkerson Group. Rob Johnson has many years of biotech business development expertise gained while working at Onyvax. The founding partners at Alacrita are supported by more than 40 consultants with significant strategic, corporate, product development and regulatory experience in the life science sector.

Dr John Brown, Chairman of BTG plc and a member of the Alacrita Advisory Group, said, “The launch of Alacrita could not have come at a better time. With life science companies of all sizes facing a rapidly changing and challenging environment, the need to access a consultancy with significant real-world experience has never been greater. I have little doubt that the Alacrita team will quickly establish itself as the consultancy of choice for companies from the pharma, biotech and medtech industries seeking solutions that will greatly enhance their chances of success.”

Alacrita’s ability to create value for its clients is based on providing access to the right team of consultants who combine extensive international industry experience (strategic, technical and commercial), broad functional capabilities and a track record of success across the life science sector. In addition, Alacrita’s consultants are able to become involved directly in the execution of key projects, allowing clients to meet their resourcing needs at critical times in their corporate development.

To read the full release, follow the link below.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch